0
RC
Reports Corner
Leukemias – Pipeline Review, H1 2013
DescriptionDescription
Reports Cornerwww.reportscorner.com
Global Markets Direct's, 'Leukemias - Pipeline Review, H1 2013'...
Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
Global Markets Direct's, 'Leukemias - Pipeline Review, H1 2...
Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
Scope
- A snapshot of the global therapeutic scenario for L...
Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
Reasons to buy
- Identify and understand important and dive...
Brief SummaryBrief Summary
Reports Cornerwww.reportscorner.com
- Modify the therapeutic portfolio by identifying discontin...
Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Table of Contents
Table of Contents 2
List of Table...
Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Early Clinical Stage Products 28
Comparative Analys...
Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Emergent BioSolutions Inc. 48
Gamida Cell Ltd. 49
B...
Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
SuperGen, Inc. 63
Teva Pharmaceutical Industries Li...
Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Sareum Holdings plc 78
MetrioPharm AG 79
SymBio Pha...
Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Stemline Therapeutics, Inc. 93
Synageva BioPharma C...
Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co.,Lt...
Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
oblimersen sodium - Drug Profile 125
moxetumomab pa...
Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
TRU-016 - Drug Profile 157
pracinostat - Drug Profi...
Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
SBC-201 - Drug Profile 187
SyB-0702 - Drug Profile ...
Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
PU-27 - Drug Profile 210
exatecan mesylate - Drug P...
Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
DNA Methyltransferase Inhibitor - Drug Profile 240
...
Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
PQR-311 - Drug Profile 258
TBI-0301 - Drug Profile ...
Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
vincristine sulfate liposomal - Drug Profile 275
JR...
Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Microtubule Binding Agents Programme - Drug Profile...
Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Drugs For Cancer - Drug Profile 305
CKBP-002 - Drug...
Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Cell Therapy For Leukemia - Drug Profile 322
Epothi...
Table of ContentsTable of Contents
Reports Cornerwww.reportscorner.com
Contact Us 426
Disclaimer 426
For more informationFor more information
Reports Cornerwww.reportscorner.com
For more information please visit our website...
Reports Corner
Thank YouThank You
www.reportscorner.com
RC
Contact us: contact@reportscorner.com
Upcoming SlideShare
Loading in...5
×

Leukemias – pipeline review, h1 2013 - Reports Corner

210

Published on

Global Markets Direct's, 'Leukemias - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Leukemias, complete with latest updates, and special features on late-stage and discontinued projects.

https://www.reportscorner.com/reports/23242/Leukemias-%E2%80%93-Pipeline-Review,-H1-2013/

Published in: News & Politics, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
210
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
7
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Transcript of "Leukemias – pipeline review, h1 2013 - Reports Corner"

  1. 1. RC Reports Corner Leukemias – Pipeline Review, H1 2013
  2. 2. DescriptionDescription Reports Cornerwww.reportscorner.com Global Markets Direct's, 'Leukemias - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Leukemias, complete with latest updates, and special features on late-stage and discontinued projects.
  3. 3. Brief SummaryBrief Summary Reports Cornerwww.reportscorner.com Global Markets Direct's, 'Leukemias - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Leukemias, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Leukemias. Leukemias - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
  4. 4. Brief SummaryBrief Summary Reports Cornerwww.reportscorner.com Scope - A snapshot of the global therapeutic scenario for Leukemias. - A review of the Leukemias products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Leukemias pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
  5. 5. Brief SummaryBrief Summary Reports Cornerwww.reportscorner.com Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Leukemias. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Leukemias pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  6. 6. Brief SummaryBrief Summary Reports Cornerwww.reportscorner.com - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  7. 7. Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com Table of Contents Table of Contents 2 List of Tables 8 List of Figures 10 Introduction 11 Global Markets Direct Report Coverage 11 Leukemias Overview 12 Therapeutics Development 13 An Overview of Pipeline Products for Leukemias 13 Leukemias Therapeutics under Development by Companies 15 Leukemias Therapeutics under Investigation by Universities/Institutes 23 Late Stage Products 26 Comparative Analysis 26 Mid Clinical Stage Products 27 Comparative Analysis 27
  8. 8. Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com Early Clinical Stage Products 28 Comparative Analysis 28 Discovery and Pre-Clinical Stage Products 29 Comparative Analysis 29 Leukemias Therapeutics – Products under Development by Companies 30 Leukemias Therapeutics – Products under Investigation by Universities/Institutes 38 Companies Involved in Leukemias Therapeutics Development 40 Boehringer Ingelheim GmbH 40 Amgen Inc. 41 Eli Lilly and Company 42 Athersys, Inc. 43 GlaxoSmithKline plc 44 Seattle Genetics, Inc. 45 MedImmune LLC 46 Daiichi Sankyo Company, Ltd 47
  9. 9. Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com Emergent BioSolutions Inc. 48 Gamida Cell Ltd. 49 BioLineRx, Ltd. 50 Amorfix Life Sciences Ltd. 51 Bio-Path Holdings, Inc. 52 ZIOPHARM Oncology, Inc. 53 Novartis AG 54 Aphios Corporation 55 CK Life Sciences Int'l., (Holdings) Inc. 56 Daewoong Pharmaceutical Co., Ltd. 57 Genta Incorporated 58 GTC Biotherapeutics, Inc. 59 Nippon Shinyaku Co., Ltd. 60 Ono Pharmaceutical Co., Ltd. 61 Pfizer Inc. 62
  10. 10. Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com SuperGen, Inc. 63 Teva Pharmaceutical Industries Limited 64 Genmab A/S 65 Merck KGaA 66 Celldex Therapeutics, Inc. 67 Marshall Edwards, Inc. 68 MethylGene Inc 69 Northwest Biotherapeutics, Inc. 70 Telik, Inc. 71 Mundipharma International Limited 72 Pharmacyclics, Inc. 73 Cytomedix, Inc. 74 Array BioPharma Inc. 75 Threshold Pharmaceuticals, Inc. 76 CrystalGenomics, Inc.
  11. 11. Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com Sareum Holdings plc 78 MetrioPharm AG 79 SymBio Pharmaceuticals Limited 80 Abiogen Pharma S.p.A. 81 Multimmune GmbH 82 Nerviano Medical Sciences S.r.l. 83 ViroStatics, srl 84 MAT Biopharma 85 Celator Pharmaceuticals, Inc. 86 Hawthorn Pharmaceuticals, Inc. 87 ACT Biotech, Inc. 88 Constellation Pharmaceuticals, Inc. 89 Deciphera Pharmaceuticals, LLC 90 MSM Protein Technologies, Inc. 91 Reata Pharmaceuticals, Inc. 92
  12. 12. Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com Stemline Therapeutics, Inc. 93 Synageva BioPharma Corp. 94 MolMed S.p.A. 95 NOXXON Pharma AG 96 Morphogenesis, Inc. 97 SBI Biotech Co., Ltd. 98 Tragara Pharmaceuticals, Inc. 99 Cellceutix Corporation 100 PharmaMar, S.A. 101 Cylene Pharmaceuticals, Inc. 102 Lipopharma 103 Keystone Nano, Inc. 104 Toko Pharmaceutical Industries Co., Ltd. 105 Cancer Therapeutics CRC Pty Ltd 106 EpiZyme, Inc. 107
  13. 13. Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co.,Ltd. 108 iCeutica, Inc. 109 Polaris Group 110 XBiotech USA, Inc. 111 Wellstat Biologics Corporation 112 Immunovative Therapies, Ltd. 113 Advancell 114 Leukemias – Therapeutics Assessment 115 Assessment by Monotherapy Products 115 Assessment by Combination Products 116 Assessment by Route of Administration 117 Assessment by Molecule Type 119 Drug Profiles 122 StemEx - Drug Profile 122 alvocidib - Drug Profile 124
  14. 14. Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com oblimersen sodium - Drug Profile 125 moxetumomab pasudotox - Drug Profile 128 brentuximab vedotin - Drug Profile 130 CDX-1127 - Drug Profile 134 acadesine - Drug Profile 135 MultiStem - Drug Profile 137 mocetinostat - Drug Profile 140 ibrutinib - Drug Profile 143 ENKASTIM-ev - Drug Profile 146 mi-APO - Drug Profile 147 AT-9283 - Drug Profile 148 ALD-151 - Drug Profile 150 IMD-5 - Drug Profile 151 bafetinib - Drug Profile 152 cilengitide - Drug Profile 154
  15. 15. Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com TRU-016 - Drug Profile 157 pracinostat - Drug Profile 159 TG-02 - Drug Profile 161 ARRY-520 - Drug Profile 163 forodesine hydrochloride - Drug Profile 165 CXCR4 Antibody - Drug Profile 167 TLK-58747 - Drug Profile 168 TG-20 - Drug Profile 169 TH-302 - Drug Profile 170 darinaparsin - Drug Profile 177 (cytarabine + daunorubicin) - Drug Profile 179 SL-202 - Drug Profile 181 SL-201 - Drug Profile 182 HSV-TK - Drug Profile 183 HSV-TK - Drug Profile 185
  16. 16. Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com SBC-201 - Drug Profile 187 SyB-0702 - Drug Profile 188 NOX-A12 - Drug Profile 189 MG-1 - Drug Profile 191 Kevetrin - Drug Profile 192 BP-100-1.02 - Drug Profile 195 sirolimus + [decitabine] - Drug Profile 196 ACTB-1011 - Drug Profile 197 DI-B4 - Drug Profile 198 tamibarotene - Drug Profile 199 tamibarotene - Drug Profile 201 lurbinectedin - Drug Profile 203 bardoxolone - Drug Profile 205 Combotox - Drug Profile 207 silmitasertib - Drug Profile 208
  17. 17. Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com PU-27 - Drug Profile 210 exatecan mesylate - Drug Profile 211 AMG-900 - Drug Profile 213 ADI-PEG 20 - Drug Profile 215 Allogeneic Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes - Drug Profile 218 buparlisib - Drug Profile 220 palbociclib - Drug Profile 223 HGC-1 - Drug Profile 226 Autologous CD19 Specific T-cell Infusion + [cyclophosphamide] + [fludarabine phosphate] + Leukapheresis - Drug Profile 227 PHA-793887 - Drug Profile 228 GNKG-168 - Drug Profile 229 Minerval - Drug Profile 231 ofatumumab - Drug Profile 233 XIAP-cIAP - Drug Profile 237 Anti-Tac(Fv)-PE38 Immunotoxin - Drug Profile 238
  18. 18. Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com DNA Methyltransferase Inhibitor - Drug Profile 240 F-14512 - Drug Profile 241 CA-18-C-3 - Drug Profile 242 MAT-303 - Drug Profile 243 LY-2090314 - Drug Profile 244 Vivia-009 - Drug Profile 245 DCC-2618 - Drug Profile 246 GO-203-2c - Drug Profile 247 BI-836826 - Drug Profile 248 PRI-724 - Drug Profile 249 CEP-37309 - Drug Profile 250 ABT-199 - Drug Profile 251 Leukothera - Drug Profile 254 Interleukin-1 Receptor Associated Protein Targeting Antibody - Drug Profile 255 MSM-112 - Drug Profile 257
  19. 19. Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com PQR-311 - Drug Profile 258 TBI-0301 - Drug Profile 259 Lenaldekar - Drug Profile 260 IC-1208 - Drug Profile 261 IB-05202 - Drug Profile 262 Drug Targeting FAK, FLT3 And VEGFR3 - Drug Profile 263 OTX-015 - Drug Profile 265 BL-8040 - Drug Profile 266 ONO-4059 - Drug Profile 268 NCL49-1 - Drug Profile 269 metformin - Drug Profile 270 Anti-CD19-CAR-Transduced T Cells - Drug Profile 271 ATX-101 - Drug Profile 272 Fas Program - Drug Profile 273 Monoclonal Antibodies Targeting CD38 - Drug Profile 274
  20. 20. Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com vincristine sulfate liposomal - Drug Profile 275 JRP-890 - Drug Profile 276 JRP-980 - Drug Profile 277 VS-1020 - Drug Profile 278 VS-1022 - Drug Profile 279 VS-1023 - Drug Profile 280 VS-1032 - Drug Profile 281 VS-1033 - Drug Profile 282 VS-1034 - Drug Profile 283 VS-1035 - Drug Profile 284 V-SlOlO - Drug Profile 285 Drug Targeting Menin - Drug Profile 286 BET Inhibitor Program - Drug Profile 287 Tumor-Derived Lymphocytes + Allogeneic Hematopoietic Stem Cell Transplantation - Drug Profile 288 EPZ-004777 - Drug Profile 289
  21. 21. Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com Microtubule Binding Agents Programme - Drug Profile 290 Aloe-Emodin Glycoside - Drug Profile 291 IB-06F259 - Drug Profile 292 Genetically Modified T Cell - Drug Profile 293 Compound-22 - Drug Profile 294 interferon alfa-2b biosimilar - Drug Profile 295 Reprogrammed T Cells - Drug Profile 296 VAY-736 - Drug Profile 297 CG-203306 - Drug Profile 298 SNG-8033 - Drug Profile 299 XGP-210 - Drug Profile 300 XGP-215 - Drug Profile 301 Drug For Leukemia - Drug Profile 302 Triplebody 19x16x19 - Drug Profile 303 Triplebody 123x16x33 - Drug Profile 304
  22. 22. Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com Drugs For Cancer - Drug Profile 305 CKBP-002 - Drug Profile 306 MSK-777 - Drug Profile 307 MSK-747 - Drug Profile 308 PMA-411R - Drug Profile 309 PV-327 - Drug Profile 310 Halistatin-1 - Drug Profile 311 Mabion CD20 - Drug Profile 312 Halistatin-2 - Drug Profile 314 filgrastim - Drug Profile 315 TAB-08 - Drug Profile 316 etomoxir - Drug Profile 318 KU-135 - Drug Profile 319 Carbazole Derivatives - Drug Profile 320 Laulimalide Derivatives - Drug Profile 321
  23. 23. Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com Cell Therapy For Leukemia - Drug Profile 322 Epothilone Analogues - Drug Profile 323 Compound-8f - Drug Profile 324 Compound-11d - Drug Profile 325 Leukemias Therapeutics – Drug Profile Updates 326 Leukemias Therapeutics – Discontinued Products 407 Leukemias Therapeutics - Dormant Products 408 Leukemias – Product Development Milestones 414 Featured News & Press Releases 414 Appendix 425 Methodology 425 Coverage 425 Secondary Research 425 Primary Research 425 Expert Panel Validation 425
  24. 24. Table of ContentsTable of Contents Reports Cornerwww.reportscorner.com Contact Us 426 Disclaimer 426
  25. 25. For more informationFor more information Reports Cornerwww.reportscorner.com For more information please visit our website https://www.reportscorner.com/reports/23242/Leukemias-%E2%80%93-Pipeline- Review,-H1-2013/
  26. 26. Reports Corner Thank YouThank You www.reportscorner.com RC Contact us: contact@reportscorner.com
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×